WO1994009039A1 - Nouvelle proteine extraite de la sangsue sylvestre haemadipsa sylvestris, qui augmente le temps de coagulation - Google Patents
Nouvelle proteine extraite de la sangsue sylvestre haemadipsa sylvestris, qui augmente le temps de coagulation Download PDFInfo
- Publication number
- WO1994009039A1 WO1994009039A1 PCT/EP1993/002793 EP9302793W WO9409039A1 WO 1994009039 A1 WO1994009039 A1 WO 1994009039A1 EP 9302793 W EP9302793 W EP 9302793W WO 9409039 A1 WO9409039 A1 WO 9409039A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- factor
- leu
- amino acid
- new protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the new protein (PT factor) has the following physicochemical properties.
- the protein shows two bands, which are assigned a molecular mass of 8200 ⁇ 2000 Da and 18600 ⁇ 2000 Da (FIG. 2).
- Example 8a In the APTT test (Example 8a) and in the PT test (Example 8b), the protein in each case shows significant increases in the plasma coagulation time. Furthermore, it shows a specific factor Xa inhibition in a factor Xa inhibition test (example 8d). In an analog factor VII-He test (FIG. 3b) an inhibitory effect is also found; however, this can also occur indirectly through the inhibition of factor Xa.
- the proteins determined the following N-terminal amino acid sequence:
- the new proteins can be obtained from the country's blood leeches
- the proteins can be further purified from the solution obtained in this way by chromatographic methods, preferably ion exchange chromatography and / or reversed phase HPLC.
- the purification of the proteins can be followed using the activity tests described in Example 8.
- a cDNA library is created from the leech in a manner known per se.
- the gene coding for the protein according to the invention can be isolated from this gene bank by, for example, producing a DNA sample whose sequence is obtained from the N-terminal amino acid sequence described above by back-translation according to the genetic code. The corresponding gene can be found and isolated by hybridization with this DNA sample.
- a primer the sequence of which was obtained by back-translation from the N-terminal amino acid sequence described above
- a second primer the sequence of which is complementary to the 3 'end of the cDNA gene fragment, preferably with the sequence poly (dT)
- the corresponding gene can also be isolated by creating an expression gene bank of leeches and screening them with an antibody which is directed against the protein according to the invention.
- the corresponding gene After the corresponding gene has been isolated, it can be genetically engineered in organisms, e.g. in bacteria, yeasts or higher eukaryotic cells can be expressed in a manner known per se with the aid of an expression vector.
- the protein can be isolated from these recombinant host systems on the basis of the physicochemical properties described above.
- the protein according to the invention is preferably used in the form of its pharmaceutically acceptable salts.
- the new protein has anticoagulant properties. It can be used, for example, for the prophylaxis of thromboses or arterial reocclusions, for the treatment of thromboses, for the preservation of blood or for extracorporeal circulation.
- the new protein is an effective anticoagulant. It can be used alone or together with known coagulation factors, for example thrombin inhibitors such as hirudin, as a medicament.
- 150 g of live landing gel (Haemadipsa sylvestris) were homogenized in 400 ml of 20 mM sodium phosphate buffer (pH 7.4) with a mixer at 4 ° C. for 10 minutes. The homogenate was centrifuged for 15 minutes at 2000 rpm (Sorvall RC-5B, rotor GS-3) and then after removing the precipitate for 30 minutes at 8000 rpm. The precipitate was discarded and the supernatant was diluted to a volume of about 600 ml with 50 mM tris (hydroxymethyl) amino methane / HCl buffer pH 8.5 (Tris / HCl buffer).
- the protein solution had a volume of 580 ml, the protein concentration was 4.49 mg / ml and the thrombin-inhibiting activity was 22.2 U / ml.
- the coagulation time (APTT, see Example 8) of the blood was prolonged by about 200 sec in a 1:10 dilution and the partial thromboplastin time (PT) was prolonged by about 60 sec in a 1:10 dilution.
- the new protein can be purified from homogenates of leech heads.
- the leeches were first decapitated and the head preparations obtained in this way were homogenized in an analogous manner.
- Purification from leech heads has the advantage that the homogenate contains a smaller amount of protein with approximately the same amount of activity.
- the new protein is already here in a higher purity.
- a significantly reduced proteolytic activity was determined in the head homogenate.
- the disadvantage of isolation from leech heads is the limited amount of substance.
- the protein solution obtained from the Egelhomogenaten was (50-100 ml, 2.5 cm diameter) on a 8.5 equilibrated with 50 mM Tris / HCl buffer pH Q-Sepharose ® column applied. After washing away unbound material with the equilibration buffer, the bound proteins were washed with a
- the new protein elutes from the column at a salt concentration of 300 to 500 mM NaCl.
- the value fraction of the Q-Sepharose chromatography was concentrated using a 3000 D membrane (Filtron Omega Alpha Cat. No. AM003062) and buffered to 20 mM succinic acid buffer pH 4.0 or simply with the succinic acid buffer pH 4.0 diluted and the pH adjusted if necessary. This fraction was applied to an S-Sepharose FF column (diameter 1.5-2.5 cm, volume 10-30 ml) equilibrated with 20 mM succinic acid at a flow of 40-80 ml / h. After washing away unbound material with equilibration buffer, the bound proteins were eluted from the column using a linear gradient from 0 to 1 M NaCl in 20 mM succinic acid pH 4.0. The elution was monitored at 280 nm in the UV and
- the value fraction of S-Sepharose chromatography was dissolved in the smallest possible volume of 0.1% by weight trifluoroacetic acid and on a reversed phase (r) HPLC column (BioRad rp304) after 5 minutes of rinsing with 0.1% by weight.
- Trifluoroacetic acid using a linear gradient (0.1 wt .-% TFA in water / 0.1 wt .-% TFA in acetonitrile in 65 min to 0.1 wt .-% TFA in 50% acetonitrile) .
- the one from the HPLC column Eluting proteins were detected by UV detection at 210 nm and fractionated by hand.
- the PT-prolonging activity contained in the individual fractions was determined after removing the solvent and resuspending in water.
- the PT factor eluted between 20 and 28% acetonitrile from the column under these conditions.
- Electrophoresis was carried out as described by Schgger and Jagow (Analytical Biochemistry, 166, 368-379 (1987)). An aliquot (20 ⁇ g) was separated on a 16% Tris / Tricine gel (BAI GmbH, Bensheim). Fig. 3 shows the result after staining the gel with Coomassie Brillant Blau (A) or Silber (B). The new protein (A: lane 2; B: lane 2) shows two bands with molecular masses of 8200 ⁇ 1000 and 18600 ⁇ 2000 Da.
- the new factor was tested in various assay systems to determine how and which factors in the coagulation cascade are inhibited by it.
- APTT activated partial thromboplastin time
- the samples were diluted as described above, with the modification that the corresponding chromogenic substrate (25 ⁇ l) was pipetted in.
- the new protein very effectively inhibits both factor Xa and the formation of factor VIIa.
- Thrombin (Boehringer / Mannheim) became a final concentration of (25 mU / ml) in phosphate buffered saline (PBS) (0.8 g / 1 NaCl; 0.2 g / 1 HCl; 0.144 g / 1 sodium phosphate; 0 , 2 g / 1 potassium phosphate, pH 7.5).
- PBS phosphate buffered saline
- Chromozym TH (Boehringer / Mannheim) was dissolved in 20 ml H 2 0 / bottle.
- chromozyme 50 ⁇ l of chromozyme as well as 25 ⁇ l of sample or buffer were added to the wells of a microtiter plate. Immediately afterwards, the absorption at 405 nm was measured at time 0 and after 30 min at 37 ° C. If the sample had a strong intrinsic color, a further control without thrombin was treated as above.
- FIG. 2 Tris / Tricine - SDS polyacrylamide gel electrophoresis
- the molar mass of the value fraction of the (r) HPLC separation was determined on a 16% Tris / Tricine gel.
- Lanes 1.3 Molar mass calibration substance, intact myoglobin 17.2 kDa, cyanogen bromide peptide myoglobin I + III 14.6 kDa, cyanogen bromide cyanide 8.2 kDa, cyanogen bromide cyanide 6.4 kDa, cyanogen bromide cyanide 2.6 kDa,
- FIG. 3 Measurement of the influence of PT factor on extrinsic coagulation.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne une protéine extraite de sangsues sylvestres du genre Haemadipsa dont la séquence aminoacide N-terminale est la suivante : A-Val-Lys-Phe-Cys-Gly-His-Pro-Leu-Ser-Leu-Pro-Thr-Ala-Leu-Cys-Ala, dans laquelle A désigne un aminoacide n'ayant pas à être déterminé de manière univalente. La protéine est appropriée pour lutter contre des maladies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19924234921 DE4234921A1 (de) | 1992-10-16 | 1992-10-16 | Neues, die Gerinnungszeit des Blutes verlängerndes Protein aus dem Landblutegel Haemadipsa sylestris |
DEP4234921.4 | 1992-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994009039A1 true WO1994009039A1 (fr) | 1994-04-28 |
Family
ID=6470630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/002793 WO1994009039A1 (fr) | 1992-10-16 | 1993-10-12 | Nouvelle proteine extraite de la sangsue sylvestre haemadipsa sylvestris, qui augmente le temps de coagulation |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE4234921A1 (fr) |
WO (1) | WO1994009039A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501241B1 (en) | 2012-09-17 | 2013-08-06 | Biopep Solutions, Inc. | Treating cancer with a whole, leech saliva extract |
CN108101975A (zh) * | 2017-12-14 | 2018-06-01 | 中国科学院昆明动物研究所 | 一种森林山蛭抗血栓多肽Sylvestin及其体外表达制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0346894A2 (fr) * | 1988-06-16 | 1989-12-20 | Merrell Dow Pharmaceuticals Inc. | Extraction et purification d'une substance anticoagulante de la sangsue d'amérique du sud, haementeria ghilianii |
EP0352903A2 (fr) * | 1988-06-24 | 1990-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Facteur inhibant le facteur Xa bovin et compositions pharmaceutiques le contenant |
WO1993011239A1 (fr) * | 1991-11-26 | 1993-06-10 | Basf Aktiengesellschaft | Nouvelles proteines inhibitrices de thrombine provenant de la sangsue des campagnes |
-
1992
- 1992-10-16 DE DE19924234921 patent/DE4234921A1/de not_active Withdrawn
-
1993
- 1993-10-12 WO PCT/EP1993/002793 patent/WO1994009039A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0346894A2 (fr) * | 1988-06-16 | 1989-12-20 | Merrell Dow Pharmaceuticals Inc. | Extraction et purification d'une substance anticoagulante de la sangsue d'amérique du sud, haementeria ghilianii |
EP0352903A2 (fr) * | 1988-06-24 | 1990-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Facteur inhibant le facteur Xa bovin et compositions pharmaceutiques le contenant |
WO1993011239A1 (fr) * | 1991-11-26 | 1993-06-10 | Basf Aktiengesellschaft | Nouvelles proteines inhibitrices de thrombine provenant de la sangsue des campagnes |
Non-Patent Citations (1)
Title |
---|
M. SCHARF ET AL.: "Primary structures of new 'iso-hirudins'", FEBS LETTERS, vol. 255, no. 1, September 1989 (1989-09-01), AMSTERDAM NL, pages 105 - 110 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9149498B2 (en) | 2012-09-17 | 2015-10-06 | Biopep Solutions, Inc. | Treating a parasitic disease with a whole, leech saliva extract |
US9265802B2 (en) | 2012-09-17 | 2016-02-23 | Biopep Solutions, Inc. | Treating colorectal cancer with a whole, leech saliva extract |
US8784896B2 (en) | 2012-09-17 | 2014-07-22 | Biopep Solutions, Inc | Antioxidant therapy with a whole, leech saliva extract |
US8790711B2 (en) | 2012-09-17 | 2014-07-29 | Biopep Solutions, Inc. | Treating diabetes with a whole, leech saliva extract |
US8962034B2 (en) | 2012-09-17 | 2015-02-24 | Biopep Solutions, Inc. | Antiviral therapy with a whole, leech saliva extract |
US9017732B1 (en) | 2012-09-17 | 2015-04-28 | Biopep Solutions, Inc. | Antibacterial therapy with a whole, leech saliva extract |
US8685462B1 (en) | 2012-09-17 | 2014-04-01 | Biopep Solutions, Inc. | Whole, leech saliva product and applications thereof |
US9265803B2 (en) | 2012-09-17 | 2016-02-23 | Biopep Solutions, Inc. | Treating a melanoma with a whole, leech saliva extract |
US8501241B1 (en) | 2012-09-17 | 2013-08-06 | Biopep Solutions, Inc. | Treating cancer with a whole, leech saliva extract |
US9433648B2 (en) | 2012-09-17 | 2016-09-06 | Biopep Solutions, Inc. | Treating renal cancer with a whole, leech saliva extract |
US9433649B2 (en) | 2012-09-17 | 2016-09-06 | Biopep Solutions, Inc. | Treating a lymphoma with a whole, leech saliva extract |
US9480720B1 (en) | 2012-09-17 | 2016-11-01 | Biopep Solutions, Inc. | Treating damaged dermal or mucosal tissue with a whole, leech saliva extract |
US9597361B2 (en) | 2012-09-17 | 2017-03-21 | Biopep Solutions, Inc. | Treating a bacterial skin infection with a whole, leech saliva extract |
US10064897B2 (en) | 2012-09-17 | 2018-09-04 | Biopep Solutions, Inc. | Treating a bacterial skin infection with a whole, leech saliva extract |
CN108101975A (zh) * | 2017-12-14 | 2018-06-01 | 中国科学院昆明动物研究所 | 一种森林山蛭抗血栓多肽Sylvestin及其体外表达制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
DE4234921A1 (de) | 1994-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68920915T2 (de) | Extraktion und Reinigung einer Antigerinnungssubstanz aus den südamerikanischen Blutegeln Haementeria ghilianii. | |
EP0142860A2 (fr) | Désulfatohirudine, son procédé de préparation et agent pharmaceutique | |
DE69823218T2 (de) | Aminoterminal verkürztes mcp-2 als chemokin antagonist | |
DE68918246T2 (de) | Verbindungen zur Verhinderung von Thrombose. | |
DD297977A5 (de) | Verfahren zur reinigung von annexinen | |
Chopin et al. | Amino acid sequence determination and biological activity of therin, a naturally occuring specific trypsin inhibitor from the leech Theromyzon tessulatum | |
EP0616642B1 (fr) | Nouvelles proteines inhibitrices de thrombine provenant de la sangsue des campagnes | |
EP0318703A1 (fr) | Préparation par génie génétique de la protéine anticoagulante PP4 | |
WO1994009039A1 (fr) | Nouvelle proteine extraite de la sangsue sylvestre haemadipsa sylvestris, qui augmente le temps de coagulation | |
WO2002040512A2 (fr) | Beta-defensine-3 humaine | |
DE4140381A1 (de) | Neue synthetische isohirudine mit verbesserter stabilitaet | |
EP0677107B1 (fr) | Inhibiteur de thrombine provenant de salive de protostomiens | |
EP0612349B1 (fr) | Nouvelle proteine inhibitrice de la trombine isolee dans les reduves | |
EP0610246B1 (fr) | Nouvelle proteine inhibitrice de la trombine isolee dans les tiques | |
EP0493494A1 (fr) | Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques | |
DE3850407T2 (de) | Protein mit inhibierender wirkung auf die entzündungserregende phospholipase a2. | |
DE4427531A1 (de) | Humanes zirkulierendes beta-Defensin hBD-1 | |
WO2002066513A2 (fr) | Fragments humains de lekti circulants hf7072, hf7638 et hf14448 ainsi que leur utilisation | |
DE4134814A1 (de) | Neues thrombininhibitorisches protein aus zecken | |
Brandt et al. | Variants of wheat histone H1 with N-and C-terminal extensions | |
EP0364942A2 (fr) | Isohirudine | |
DE4031731A1 (de) | Protein aus hirudo medicinalis | |
EP0502876B1 (fr) | Nouvelles proteines dissolvant les caillots sanguins, et leur preparation a partir de la sangsue hirudo medicinalis | |
DE60126026T2 (de) | PROTEIN MIT HäMOLYTISCHER AKTIVITäT UND DIESES PROTEIN KODIERENDE GEN | |
DE19724791B4 (de) | Thrombin hemmende Peptide, deren Verwendung und diese enthaltende pharmazeutische Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WA | Withdrawal of international application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |